September 2023, Vol 13, No 9

Physicians have one of the highest suicide rates of any profession. According to the American Foundation for Suicide Prevention, an estimated 300 physicians die by suicide each year across the United States—nearly 1 per day. Read More ›

Opioids such as morphine are the gold standard for treating cancer-induced bone pain, but new University of Arizona Health Sciences research recently published in PAIN uncovered a mechanism by which chronic morphine use may increase bone loss and pain. Read More ›

Chicago, IL—It is well documented that clinical trials thus far have for the most part excluded underserved populations, and that means the results of these trials cannot be generalized to society at large. Fortunately, the federal government and medical societies have taken aim at remedying this imbalance in accrual for clinical trials. Read More ›

According to the American Cancer Society, approximately 288,300 men in the United States will be diagnosed with prostate cancer in 2023 and 34,700 deaths will be attributed to the disease. September is Prostate Cancer Awareness Month, a time designated to help people learn more about the disease and to support those who are affected. Read More ›

Successful revenue cycle management is a team effort that requires continuous collaboration across multiple departments of an organization. Although all institutions aim for standard industry best practices, the way in which these goals are attained may vary greatly, based on unique workflows, workforces, and needs. Read More ›

Peer-to-peer (PTP) support is an important aspect of nonprofessional patient care that improves cancer-specific quality of life. However, PTP research is sorely lacking, with very few randomized controlled trials being conducted in this space, as well as a lack of standardized quality parameters for what constitutes successful and efficient PTP support, according to newly published research. Read More ›

Cancer researchers continue to make progress in developing tests using liquid biopsies that could complement and even serve as an alternative to traditional tissue biopsies. These tests, which analyze bits of free-floating genetic and other material shed by tumors into the blood and other body fluids, are already being used to detect cancer-related genetic changes and guide treatment decisions. Read More ›

On August 14, 2023, the FDA accelerated the approval of elranatamab-bcmm (Elrexfio; Pfizer), a bispecific B-cell maturation antigen–directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Read More ›

On August 9, 2023, the FDA accelerated the approval of talquetamab-tgvs (Talvey; Janssen Biotech), a bispecific GPRC5D-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory multiple myeloma who have previously received at least 4 lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Read More ›

On August 11, 2023, the FDA accelerated the approval of the fixed-dose combination of niraparib and abiraterone acetate (Akeega; Janssen Biotech), with prednisone, for the treatment of adults with deleterious or suspected deleterious BRCA-mutated, castration-resistant prostate cancer, as determined by an FDA-approved test. The FDA granted this approval priority review. Read More ›